Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer-Reference-Cited by-同舟云学术

Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer

Published:2020-04-16 Issue:4 Volume:15 Page:e0231895
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ding Yuqin^ORCID,Ding Kaijing,Qian Hongdan,Yu Xingfei,Zou Dehong,Yang Hongjian,Mo Wenju,He Xiangming,Zhang Fanrong,Qin Chengdong,Zheng Yurong,Ding Xiaowen

Funder

Hangzhou Health Commission

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference28 articles.

1. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis;LM Spring;JAMA Oncol,2016

2. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials;C Davies;Lancet (London, England).,2011

3. Effect of screening and adjuvant therapy on mortality from breast cancer;DA Berry;The New England journal of medicine,2005

4. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS);AM Thompson;Breast cancer research: BCR,2010

5. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy;M Kasami;Breast (Edinburgh, Scotland).,2008

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterogeneity in the Primary Lesions of invasive micropapillary breast carcinoma.;Current Problems in Cancer: Case Reports;2024-09

2. Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?;Scientific Reports;2024-06-25

3. Predictors of Endocrine Resistance in a Cohort of Mexican Breast Cancer Patients;2024-05-30

4. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China;World Journal of Surgical Oncology;2024-04-06

5. Prognostic value of receptor status conversion after neoadjuvant chemotherapy in breast cancer patients;2024-03-20